Syndax: HDAC double-play

With an exclusive license to IP covering the combined use of HDAC inhibitors and nuclear receptor ligands to treat cancer, a newly acquired selective HDAC inhibitor and $40 million in cash, Syndax Pharmaceuticals Inc. believes it has carved out a unique and protected position in an already crowded space.

Syndax (Waltham, Mass.) was formed in 2005 based on an exclusive license to IP from the Salk Institute

Read the full 664 word article

How to gain access

Continue reading with a
two-week free trial.